Last edition
News about "Suven Life Sciences"
Suven Completes Phase 3 Enrollment of Masupirdine for Alzheimer's-Related Agitation
Suven Life Sciences completes enrollment in its global Phase 3 masupirdine trial, with 424 patients randomised to evaluate the therapy for agitation associated with Alzheimer’s dementia.
Suven Life Sciences | 05/09/2026 | By News Bureau
Suven Life Sciences will showcase its differentiated CNS clinical portfolio at BIO International Convention 2026, featuring late-stage drug candidates for Alzheimer’s agitation, Major Depressive Disorder (MDD), narcolepsy, Parkinson’s-related cognitive impairment, and other CNS disorders.
Suven Life Sciences | 22/06/2026 | By News Bureau | 170
Suven Life Sciences reported positive phase 2b results for Ropanicant in Major Depressive Disorder (MDD), achieving significant improvements in depression symptoms versus placebo. The treatment showed favorable safety and tolerability, with no withdrawal symptoms or dissociation, supporting advancement into a global phase 3 study.
Suven Life Sciences | 17/06/2026 | By News Bureau | 381
Suven Life Sciences Reports Positive Phase 1 Results for SUVN-I6107
Suven Life Sciences has reported positive topline results from the First-in-Human phase 1 study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM). The successful trial supports the advancement of SUVN-I6107 into phase 2 clinical development.
Suven Life Sciences | 16/06/2026 | By News Bureau | 217
Suven Life Sciences Announces 3 Poster Presentations on Samelisant
Suven Life Sciences showcases 3 posters on Samelisant (SUVN-G3031), including findings from the global phase 3 AWAKE Narcolepsy Study at SLEEP 2026.
Suven Life Sciences | 12/06/2026 | By News Bureau | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy